Table 4.
Frequency of common adverse events in each treatment group (number of subjects)
| Event, n (%) | rHSA/IFNα2a 600 μg (n = 8) | rHSA/IFNα2a 750 μg (n = 8) | rHSA/IFNα2a 900 μg (n = 8) | Peg‐IFNα2a 180 μg (n = 8) |
|---|---|---|---|---|
| Albumin decreased | 5 | 4 | 3 | 6 |
| White blood cell count decreased | 5 | 7 | 3 | 6 |
| Haemoglobin decreased | 1 | 3 | 2 | 5 |
| Platelet count decreased | 4 | 3 | 5 | 6 |
| Neutrophil absolute value decreased | 6 | 8 | 6 | 7 |
| Vomit | 0 | 0 | 2 | 0 |
| Back pain | 0 | 0 | 1 | 1 |
| Fever | 1 | 2 | 4 | 3 |
| Fatigue | 0 | 2 | 5 | 1 |
| Ache all over | 0 | 2 | 0 | 3 |
| Headache | 0 | 4 | 1 | 5 |
| Dizziness | 0 | 0 | 3 | 1 |
| Knee‐joint pain | 0 | 1 | 1 | 0 |
| Drowsiness | 0 | 0 | 3 | 0 |